Insomnia: Types, Causes & Evidence-Based Treatment

Insomnia is a sleep disorder characterized by persistent difficulty initiating sleep, maintaining sleep, or waking too early with inability to return to sleep, despite adequate opportunity for sleep. To meet diagnostic criteria for chronic insomnia disorder, these difficulties must occur at least three nights per week for at least three months and cause meaningful daytime impairment.

Insomnia is the most common sleep complaint, affecting 30-35% of adults intermittently and 10-15% chronically. Unlike acute insomnia (lasting days to weeks in response to stress), chronic insomnia persists due to behavioral and cognitive patterns that maintain the sleep difficulty long after the original trigger resolves.

The condition significantly impacts quality of life, work performance, relationships, and physical health. It is associated with increased risk of depression, anxiety disorders, cardiovascular disease, and impaired immune function. Effective evidence-based treatments exist, with cognitive behavioral therapy for insomnia (CBT-I) recommended as the first-line treatment by all major sleep medicine organizations.

By Duration

• Acute (short-term) insomnia: Lasts days to weeks, typically triggered by stress, travel, schedule changes, or medical illness. Usually resolves without treatment once the trigger is addressed.
• Chronic insomnia: Persists for three months or longer. Often develops when behavioral patterns (spending too long in bed, napping, clock-watching) perpetuate sleep difficulty after the initial cause has resolved.

By Presentation

• Sleep-onset insomnia: Difficulty falling asleep at the beginning of the night (sleep onset latency greater than 30 minutes)
• Sleep-maintenance insomnia: Frequent awakenings during the night with difficulty returning to sleep (wake after sleep onset greater than 30 minutes)
• Early morning awakening: Waking significantly earlier than desired with inability to fall back asleep
• Mixed presentation: Combination of multiple patterns (most common in chronic insomnia)

Insomnia is best understood through the "3P model" — Predisposing, Precipitating, and Perpetuating factors:

Predisposing Factors (Vulnerability)

• Genetic tendency toward hyperarousal
• Female sex (hormonal influences)
• Older age
• Personality traits (perfectionism, rumination)
• History of anxiety or depression

Precipitating Factors (Triggers)

• Life stressors (job loss, divorce, bereavement)
• Medical illness or pain
• Schedule disruptions (shift work, jet lag)
• Medications (stimulants, steroids, antidepressants)
• Substance use (caffeine, alcohol, cannabis)

Perpetuating Factors (Maintenance)

• Spending excessive time in bed trying to force sleep
• Irregular sleep-wake schedules
• Daytime napping to compensate
• Clock-watching and sleep-related anxiety
• Using the bed for activities other than sleep
• Catastrophizing about consequences of poor sleep

These perpetuating behaviors are the primary target of CBT-I because they maintain insomnia independently of the original trigger.

Insomnia is primarily diagnosed through clinical history and sleep diaries rather than overnight sleep studies. Your physician evaluates:

• Sleep history: Bedtime, wake time, time to fall asleep, nighttime awakenings, total sleep time
• Sleep diaries: Two weeks of daily recordings provide objective pattern data
• Daytime impact: Fatigue, concentration problems, mood disturbance, work impairment
• Medical history: Pain conditions, medications, psychiatric disorders, other sleep disorders
• Questionnaires: Insomnia Severity Index (ISI), Pittsburgh Sleep Quality Index (PSQI)

A sleep study (polysomnography) is generally not required to diagnose insomnia but may be ordered when a coexisting sleep disorder is suspected—particularly obstructive sleep apnea or periodic limb movement disorder—that could be causing the sleep disruption.

Actigraphy (a wrist-worn activity monitor) may be used to objectively document sleep-wake patterns over 1-2 weeks when there is discrepancy between reported and actual sleep timing.

CBT-I is recommended as the first-line treatment for chronic insomnia by the American Academy of Sleep Medicine, American College of Physicians, and European Sleep Research Society. It addresses the behavioral and cognitive patterns that maintain insomnia, producing durable improvements that persist long after treatment ends.

Core Components of CBT-I

• Sleep restriction therapy: Temporarily limiting time in bed to match actual sleep time, creating mild sleep deprivation that consolidates sleep and rebuilds sleep drive. Time in bed is gradually increased as efficiency improves.
• Stimulus control: Rebuilding the bed-sleep association by: going to bed only when sleepy, leaving bed if awake >15 minutes, using the bed only for sleep, maintaining consistent wake time regardless of sleep quality.
• Cognitive restructuring: Identifying and challenging unhelpful beliefs about sleep (catastrophizing, unrealistic expectations, sleep effort).
• Sleep hygiene education: Optimizing environmental and behavioral factors: consistent schedule, dark cool bedroom, limiting caffeine/alcohol, regular exercise (not within 2 hours of bed).
• Relaxation training: Progressive muscle relaxation, guided imagery, or mindfulness techniques to reduce physiological arousal.

CBT-I typically involves 4-8 sessions with a trained therapist (psychologist, nurse practitioner, or certified behavioral sleep medicine specialist). Digital CBT-I programs are also available and show comparable efficacy for many patients.

Medications may be appropriate as short-term treatment while initiating CBT-I or when CBT-I alone provides insufficient relief. Major categories include:

Benzodiazepine Receptor Agonists (Z-drugs)

Zolpidem (Ambien), eszopiclone (Lunesta), zaleplon (Sonata). Reduce sleep onset latency and increase total sleep time. Recommended for short-term use due to tolerance, dependence risk, and complex sleep behaviors.

Dual Orexin Receptor Antagonists (DORAs)

Suvorexant (Belsomra), lemborexant (Dayvigo). Newer class that blocks wakefulness-promoting orexin signaling. Lower abuse potential than Z-drugs; may be appropriate for longer-term use.

Melatonin Receptor Agonists

Ramelteon (Rozerem). Acts on melatonin receptors to promote sleep onset. Minimal abuse potential; primarily helps sleep-onset insomnia and circadian rhythm issues.

Low-Dose Antidepressants

Trazodone, doxepin (Silenor). Used off-label (trazodone) or at very low doses (doxepin 3-6mg) for sleep maintenance. Sedation is a side effect harnessed for therapeutic benefit.

All sleep medications should be prescribed and monitored by a physician. They do not address the underlying causes of chronic insomnia and are most effective when combined with behavioral interventions.

While chronic insomnia often requires professional treatment, these evidence-based strategies can improve sleep quality:

• Keep a consistent wake time — even on weekends. This anchors your circadian rhythm more effectively than bedtime consistency.
• Avoid clock-watching — turn clocks away from view to prevent calculating remaining sleep time.
• Get out of bed if awake — after approximately 15-20 minutes of wakefulness, move to another room for a quiet activity until sleepy. Return to bed only when drowsy.
• Limit caffeine after noon — caffeine has a half-life of 5-7 hours and can impair sleep even when you do not feel stimulated.
• Avoid alcohol as a sleep aid — while alcohol promotes initial sleep onset, it fragments sleep during the second half of the night and worsens insomnia over time.
• Exercise regularly — 30 minutes of moderate aerobic exercise improves sleep quality, but avoid vigorous exercise within 2-3 hours of bedtime.
• Manage worry — designate a worry time earlier in the evening to address concerns, then practice letting go of unresolved issues at bedtime.
• Optimize your sleep environment — cool (65-68F), dark, quiet, and reserved for sleep only.